Last updated 4 days ago
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
1156 patients around the world
Available in United States, Argentina
Pfizer
2Research sites
1156Patients around the world
This study is for people with
Chronic obstructive pulmonary disease
Moderate/severe copd
Requirements for the patient
To 80 Years
All Gender
Medical requirements
- Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition).Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [<] 70 percent (%) and post-bronchodilator FEV1 % predicted <70%, but greater than equal to 30%).Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months.Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.
- Significant pulmonary disease other than COPD.Requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent.Hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.
Sites
IDIM - Sede Centro - CABA
Instituto INSARES - Mendoza
StudyCOPD
SponsorPfizer
Study typeInterventional
Conditions
Moderate/severe copd
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07363694
